Log In

New? Register Here

Top Biotech & Biopharmaceutical Companies

Google has just Announced a New Health Oriented Company - Calico is a Health Company Focused on Human Health from Extending Life to Increasing Well Being. Read Full Article
Sort By:

NuPathe Inc

227 Washington Street. Suite 200
CONSHOHOCKEN, PA 19428
http://www.nupathe.com
  • Main Phone: (484) 567-0130
  • Fax Number: (484) 567-0136
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


NuPathe, Inc. develops therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. The Companys products are NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The Company completed a pivotal Phase III clinical trial for Zelrix, an active, single-use transdermal sumatriptan patch for the treatment of acute migraine.

Questcor Pharmaceuticals Inc

Suite D, 1300 North Kellogg Drive
ANAHEIM HILLS, CA 92807
http://www.questcor.com
  • Main Phone: (714) 786-4200
  • Fax Number: (714) 789-4229
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Questcor Pharmaceuticals, Inc. (Questcor) is a biopharmaceutical company. The Company is focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Its primary product is H.P. Acthar Gel (repository corticotropin injection), or Acthar, an injectable drug that is approved by the United States food and drug administration (FDA), for the treatment of 19 indications. Its research and development program is focused on: the evaluation of the use of Acthar for certain on-label indications; the investigation of other potential uses of Acthar for indications not FDA approved; and the expansion of its understanding of how Acthar works in the human body (pharmacology), and ultimately, its mechanisms of action in the disease states for which it is used, or may be used in the future. The Company sells Doral to pharmaceutical wholesalers, which resell Doral primarily to retail pharmacies and hospitals.

Synergy Pharmaceuticals Inc

Suite 1609, 420 Lexington Avenue
NEW YORK, NY 10170
http://www.synergypharma.com
  • Main Phone: (212) 297-0020
  • Fax Number: (212) 297-0019
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company s lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). It is also developing SP-333, the second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). The Company s active pharmaceutical ingredients (APIs) and the final formulated drug products are manufactured for it by third party contractors. As of December 31, 2011, the Company was developing plecanatide, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. Plecanatide is an agonist of GC-C receptor.

Exelixis Inc.

210 East Grand Avenue
SOUTH SAN FRANCISCO, CA 94080-0511
http://www.exelixis.com
  • Main Phone: (650) 837-7000
  • Fax Number: (650) 837-8300
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications. The clinical program for cabozantinib is focused on the treatment of metastatic castration-resistant prostate cancer (CRPC) and medullary thyroid cancer but also includes the evaluation of other tumor types. Cabozantinib inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth, vascularization and/or metastasis.

ArQule Inc.

19 Presidential Way
WOBURN, MA 01801-5140
http://www.arqule.com/
  • Main Phone: (781) 994-0300
  • Fax Number: (781) 376-6019
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. It employs technologies, such as its ArQule Kinase Inhibitor Platform to design and develop drugs. Its product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase (c-Met). C-Met is a target for cancer therapy, based on its multiple roles in cancerous cell proliferation, tumor spread, new blood vessel formation and resistance to certain drug therapies. It has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo in the United States, Europe, South America and the rest of the world, excluding Japan and other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin. In August 2011, Kyowa Hakko Kirin announced the initiation of the Phase III ATTENTION (Asian Trial of Tivantinib plus Erlotinib vs. Erlotinib for NSCLC without EGFR Mutation) trial of tivantinib in combination with erlotinib.

Enzon Pharmaceuticals Inc

20 Kingsbridge Road
PISCATAWAY, NJ 08854
http://enzon.com/
  • Main Phone: (732) 980-4500
  • Fax Number: (302) 655-5049
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Enzon Pharmaceuticals, Inc. (Enzon) is a biotechnology company. The Company s drug development programs utilize two platforms: Customized PEGylation Linker Technology (Customized Linker Technology) and third-generation messenger ribonucleic acid (mRNA) antagonists utilizing the Locked Nucleic Acid (LNA) technology. The Company has four compounds in human clinical development, a PEGylated version of the active metabolite of the cancer drug, irinotecan, PEG-SN38, and mRNA antagonists Survivin and the Androgen Receptor (AR). In addition, it has mRNA antagonist targets in various stages of preclinical research. The Company receives royalty revenues from licensing arrangements with other companies related to sales of products developed using its Customized Linker Technology-PEGINTRON. It is also using LNA technology to develop mRNA antagonists against oncology targets.

OSI Pharmaceuticals, LLC

1 Bioscience Park Dr.
Farmingdale, NY 11735-1019
http://www.osip.com
  • Main Phone: (631) 962-2000
  • Fax Number: (631) 752-3880
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


ImClone Systems Corporation

440 Rte. 22 East
Bridgewater, NJ 08807
http://www.imclone.com
  • Main Phone: (908) 541-8100
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Wyeth Limited

RBC, Mahindra Towers 4th Floor, 'A' Wing Dr. G.M. Bhosale Road, Worli
MUMBAI, 400098
http://www.wyethindia.com
  • Main Phone: (122) 265-7400
  • Fax Number: (122) 265-7410
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Wyeth Limited is a biopharmaceutical company. The Company operates in two segments: Pharmaceuticals and Other businesses. The Pharmaceuticals segment consists of formulations. Formulations include oral contraceptives, hormone replacement therapy, antibiotics, vaccines, steroids and other prescription medicines. Others consists of over the counter (OTC) pharmaceuticals, cosmetics and other allied consumer products. Its product portfolio consists of more than 30 brands. The Company s antibiotics include Cynomycin (Minocycline hydrochloride), Ledermycin (Demeclocycline hydrochloride), Penidure LA (Benzathine Penicillin G), Tygacil, Wymox (Amoxycillin) and Zosyn (Sterile Piperacillin Sodium and Tazobactam Sodium). Its steroids include Ledercort (Triamcinolone Tablets), Ledercort Ointment (Triamcinolone Acetonide), Wycort (Hydrocortisone Acetate) and Wysolone (Prednisolone). Women s Health product includes Loette (Levonorgestrel and Ethinyl Estradiol).

ImmunoGen Inc.

830 Winter Street
WALTHAM, MA 02451-1477
http://www.immunogen.com
  • Main Phone: (781) 895-0600
  • Fax Number: (781) 895-0611
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


ImmunoGen, Inc. (ImmunoGen) develops targeted, antibody-based therapeutics for the treatment of cancer. ImmunoGen designs linkers that enable antibody-based therapeutics for the treatment of cancer agents to remain stably attached to the antibodies while in the blood stream and be released in their fully active form after delivery to a cancer cell. An anticancer compound made using the Company s Targeted Antibody Payload (TAP), technology consists of a monoclonal antibody. The Company's TAP technology is designed to enable the creation of well-tolerated anticancer products. As of June 30, 2012, ImmunoGen had three wholly owned clinical-stage product candidates included IMGN901, IMGN853, and IMGN529, and other TAP compounds in earlier stages of development.